Clinicopathological factors associated with tumour‐specific mutation detection in plasma of patients with RAS ‐mutated or BRAF ‐mutated metastatic colorectal cancer-Reference-Cited by-同舟云学术

Clinicopathological factors associated with tumour‐specific mutation detection in plasma of patients with RAS ‐mutated or BRAF ‐mutated metastatic colorectal cancer

Published:2021-05-20 Issue:6 Volume:149 Page:1385-1397
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Hamfjord Julian¹²³^ORCID,Guren Tormod Kyrre¹⁴,Glimelius Bengt⁵,Sorbye Halfdan⁶⁷,Pfeiffer Per⁸⁹,Dajani Olav¹,Lingjærde Ole Christian²¹⁰,Tveit Kjell Magne¹³⁴,Pallisgaard Niels¹¹,Spindler Karen‐Lise Garm¹²¹³^ORCID,Kure Elin H.²¹⁴

Affiliation:

1. Department of Oncology Oslo University Hospital Oslo Norway

2. Department of Cancer Genetics Institute for Cancer Research, Oslo University Hospital Oslo Norway

3. Institute of Clinical Medicine, Faculty of Medicine University of Oslo Oslo Norway

4. K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital Oslo Norway

5. Department of Immunology, Genetics and Pathology Uppsala University Uppsala Sweden

6. Department of Oncology Haukeland University Hospital Bergen Norway

7. Department of Clinical Science University of Bergen Bergen Norway

8. Department of Oncology Odense University Hospital Odense Denmark

9. Institute of Clinical Research University of Southern Denmark Odense Denmark

10. Department of Computer Science University of Oslo Oslo Norway

11. Department of Pathology Zealand University Hospital Roskilde Denmark

12. Department of Experimental Clinical Oncology Aarhus University Hospital Aarhus Denmark

13. Institute of Clinical Medicine, Aarhus University Aarhus Denmark

14. Faculty of Technology, Natural Sciences and Maritime Sciences University of South‐Eastern Norway Campus Bø Norway

Funder

Cancerfonden

Kreftforeningen

Merck KGaA

Novo Nordisk Fonden

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33672

Reference48 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

3. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

4. K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

5. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A neuroendocrine biomarker revolution from monoanalyte to multianalyte biomarkers in non-functioning gastro-entero-pancreatic neuroendocrine neoplasms;Critical Reviews in Oncology/Hematology;2024-11

2. A panorama of colon cancer in the era of liquid biopsy;The Journal of Liquid Biopsy;2024-06

3. Liquid biopsy in colorectal cancer: Onward and upward;Critical Reviews in Oncology/Hematology;2024-02

4. Assessment of postoperative circulating tumour DNA to predict early recurrence in patients with stage I–III right-sided colon cancer: prospective observational study;BJS Open;2024-01-03

5. Unveiling the potential of proteomic and genetic signatures for precision therapeutics in lung cancer management;Cellular Signalling;2024-01